Oncology Competitors
| TOI Stock | USD 2.53 0.08 3.07% |
Oncology Institute vs Agilon Health Correlation
Average diversification
The correlation between Oncology Institute and AGL is 0.14 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Oncology Institute and AGL in the same portfolio, assuming nothing else is changed.
Moving against Oncology Stock
The current Return On Tangible Assets is estimated to decrease to -0.52. The current Return On Capital Employed is estimated to decrease to -0.6. As of now, Oncology Institute's Intangible Assets are decreasing as compared to previous years. The Oncology Institute's current Debt To Assets is estimated to increase to 0.67, while Total Assets are projected to decrease to under 178.2 M.Oncology Institute Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Oncology Institute and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Oncology and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Oncology Institute does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Oncology Stock performing well and Oncology Institute Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Oncology Institute's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EHAB | 1.67 | 0.43 | 0.20 | 1.15 | 1.54 | 4.81 | 11.79 | |||
| AUNA | 2.21 | (0.28) | 0.00 | (0.23) | 0.00 | 4.95 | 23.30 | |||
| SNDA | 1.49 | 0.41 | 0.31 | 0.70 | 0.76 | 5.62 | 17.41 | |||
| CCRN | 2.53 | (0.54) | 0.00 | (0.37) | 0.00 | 5.58 | 28.70 | |||
| EOLS | 2.78 | (0.54) | 0.00 | (0.61) | 0.00 | 4.69 | 19.71 | |||
| TMCI | 3.59 | (1.61) | 0.00 | (0.68) | 0.00 | 6.51 | 28.25 | |||
| KIDS | 1.85 | (0.04) | (0.02) | 0.04 | 2.12 | 3.72 | 16.89 | |||
| CBLL | 2.61 | 0.82 | 0.33 | 0.70 | 2.02 | 6.82 | 18.00 | |||
| AUTL | 3.95 | (0.19) | 0.00 | 0.00 | 0.00 | 10.45 | 30.76 | |||
| AGL | 4.80 | (0.42) | 0.00 | (0.05) | 0.00 | 10.00 | 30.19 |
Cross Equities Net Income Analysis
Compare Oncology Institute and related stocks such as Enhabit, Auna SA, and Sonida Senior Living Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EHAB | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 75 M | 111.1 M | (40.4 M) | (80.5 M) | (156.2 M) | (140.6 M) | (133.6 M) |
| AUNA | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 22 M | 37 M | 72.8 M | (7.3 M) | (27.1 M) | (85.2 M) | (252 M) | 110.7 M | 99.6 M | 104.6 M |
| SNDA | 3.7 M | 3 M | (3.1 M) | (16.5 M) | (24.1 M) | (14.3 M) | (28 M) | (44.2 M) | (53.6 M) | (36 M) | (295.4 M) | 125.6 M | (54.4 M) | (21.1 M) | (2.1 M) | (1.9 M) | (1.9 M) |
| CCRN | 11.5 M | 4.1 M | (42.2 M) | (34.6 M) | (31.8 M) | 4.4 M | 8 M | 37.5 M | (17 M) | (57.7 M) | (13 M) | 132 M | 186 M | 72.6 M | (14.6 M) | (16.7 M) | (15.9 M) |
| EOLS | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (20.1 M) | (4.5 M) | (46.9 M) | (90 M) | (163 M) | (46.8 M) | (74.4 M) | (61.7 M) | (50.4 M) | (45.4 M) | (47.6 M) |
| TMCI | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (3.7 M) | (20.6 M) | (42.8 M) | (49.5 M) | (55.7 M) | (50.2 M) | (47.7 M) |
| KIDS | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (7.9 M) | (6.6 M) | (8.9 M) | (12 M) | (13.7 M) | (32.9 M) | (16.3 M) | 1.3 M | (21 M) | (37.8 M) | (34 M) | (32.3 M) |
| CBLL | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (29.5 M) | (40.5 M) | (36.4 M) | (38.2 M) |
| AUTL | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (7.5 M) | (12.6 M) | (19.7 M) | (31.1 M) | (123.8 M) | (142.1 M) | (142.1 M) | (148.8 M) | (208.4 M) | (220.7 M) | (198.6 M) | (188.7 M) |
| AGL | (282.6 M) | (282.6 M) | (282.6 M) | (282.6 M) | (282.6 M) | (282.6 M) | (282.6 M) | (282.6 M) | (282.6 M) | (282.6 M) | (60.1 M) | (406.5 M) | (106.6 M) | (262.6 M) | (260.2 M) | (234.1 M) | (245.8 M) |
Oncology Institute and related stocks such as Enhabit, Auna SA, and Sonida Senior Living Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Oncology Institute financial statement analysis. It represents the amount of money remaining after all of Oncology Institute operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Oncology Institute Competitive Analysis
The better you understand Oncology Institute competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Oncology Institute's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Oncology Institute's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Oncology Institute Competition Performance Charts
Five steps to successful analysis of Oncology Institute Competition
Oncology Institute's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Oncology Institute in relation to its competition. Oncology Institute's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Oncology Institute in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Oncology Institute's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Oncology Institute, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Oncology Institute position
In addition to having Oncology Institute in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Manufacturing Thematic Idea Now
Manufacturing
Companies that provide goods across residential, commercial and industrial construction such as machinery, tools, or lumber production. The Manufacturing theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Manufacturing Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Oncology Institute Correlation with its peers. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is there potential for Health Care Equipment & Supplies market expansion? Will Oncology introduce new products? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.67) | Revenue Per Share | Quarterly Revenue Growth 0.215 | Return On Assets | Return On Equity |
Investors evaluate Oncology Institute using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Oncology Institute's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Oncology Institute's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Oncology Institute's market price signifies the transaction level at which participants voluntarily complete trades.